However, patients with drug-eluting stents
may be prescribed the antiplatelet for a year or more, Dr.
Differences in safety profile between second generation drug-eluting stents
. Subgroup analysis at 2 years from the ESTROFA-2 Spanish registry.
Elevated levels of very low-density lipoprotein cholesterol independently associated with in-stent restenosis in diabetic patients after drug-eluting stent
Lee et al., "Incidence and predictors of drug-eluting stent
fractures in long coronary disease," International Journal of Cardiology, vol.
Though drug-eluting stents
are becoming much more commonly implanted than bare-metal types, a BMS may be a more appealing option if the patient has a very high risk of bleeding or if a physician believes the patient won't be able to adhere to DAPT over a period of months or years.
Late stent malapposition risk is higher after drug-eluting stent
compared with bare-metal stent implantation and associates with late stent thrombosis.
ADAPT-DES is the largest study ever to explore the overall treatment implications of platelet reactivity on patient outcomes after successful coronary drug-eluting stent
There is controversy over whether the drug-eluting stent
or the bare metal stent has superior clinical benefit.
According to the Natick, Mass.-based cardiovascular device giant, the devices are the only drug-eluting stent
(DES) systems in the United States with an approved indication to treat patients with AMI.
A drug-eluting stent
is a peripheral or coronary stent (a scaffold) placed into narrowed, diseased peripheral or coronary arteries that slowly releases a drug to block cell proliferation.
The Food and Drug Administration has approved the Xience V drug-eluting stent
, with the requirement that the manufacturer conduct postmarketing studies, including one that follows rates of stent thrombosis and other events in recipients for 5 years.
Key Words: drug-eluting stent
, complications, perioperative complications, myocardial infarction, perioperative clopidogrel